Biotech
Córdoba Biotech Started the Process to Select 20 New Startups
Córdoba Biotech supports 28 innovative projects with training, mentoring, talent acquisition, and access to shared labs for prototype testing and market validation. The program fosters entrepreneurship within a networked community, including universities and industry partners. Financed by Imdeec, the initiative offers free resources for two years, promoting growth and talent retention in Córdoba’s biotech sector.
The Municipal Institute for Economic Development (Imdeec) has opened this Tuesday, November 5th, the period for its second call for the selection of projects and companies in the high-tech incubator Córdoba Biotech. Specifically, there are 20 vacant places for “innovative projects that work in the biomedical, agri-food or environmental fields and that need to carry out an incubation and acceleration process to consolidate their business model,” as explained this Tuesday by the first deputy mayor of the City Council, Blanca Torrent.
Interested parties can choose from four incubation modalities : in-person with an individual workspace; coworking , with shared resources; virtual and, for the first time, semi-face-to-face . Torrent has highlighted that there are projects that, although they have facilities to develop their work, need to receive business mentoring and use the laboratory “sporadically.”
Currently, Córdoba Biotech is accelerating 28 “highly innovative” projects, the president of Imdeec also highlighted
The new initiatives selected will, firstly, participate in a training and mentoring programme to improve their entrepreneurial skills and receive guidance on key aspects for their growth, scaling and attracting investments. In addition, they will have access to advanced support services to locate and select talent, to transfer innovation to the company, to attract investors and to manage financial resources or to internalise them.
Córdoba Biotech also has shared laboratories with high-value scientific-technological equipment that “allow market validation analyses, pilot tests and prototypes to be carried out,” explained Torrent. This is because “one of the main barriers to the growth of these startups and technology companies is the high investment they need in laboratories and R&D equipment.” Thirdly, researchers will have their own space within a specialized ecosystem that encourages entrepreneurship, innovation and knowledge transfer.
The Cordoba Biotech community
Finally, access to the programme allows them to join the Córdoba Biotech community, made up of Imdeec and collaborators with a high scientific-research component, such as the University of Córdoba, the Foundation for Biomedical Research of Córdoba, CaixaBank, leading companies and startups. “This community encourages networking, the generation of collaboration opportunities and facilitates contact with potential clients, partners and financiers in the sector,” Torrent stressed.
All resources are free of charge , as “Imdeec maintains and finances this initiative from its annual budget.” The maximum duration of the project is two years. The registration period will be open from today until December 31st.
Currently, Córdoba Biotech is accelerating 28 startups and business initiatives in which more than 60 specialists from the fields of biology, biochemistry, physics, IT and telecommunications work, as well as accounting, laboratory and graphic design staff. These are specialized, highly qualified jobs, many of which have been trained at the University of Córdoba, which allows us to “retain talent,” stressed the municipal delegate for Finance, Economy and Employment. “
As our slogan says, we have been changing many lives for a year, and we face this second year with the desire to continue moving forward so that Córdoba continues to grow,” she stressed.
__
(Featured image by jarmoluk via Pixabay)
DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.
This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.
First published in elDia DE CORDOBA. A third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.
Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us
-
Biotech2 weeks ago
Rovi Cuts Its Profit by 4% in the First Nine Months, to 113.5 Million
-
Biotech3 days ago
Better Care Advances Healthcare Technology with Partnership with Oracle
-
Fintech1 week ago
Fintech Company Satispay Raises 60 Million Euros Led by Addition
-
Biotech20 hours ago
ATB Therapeutics Raises €54 Million and Attracts a Pharmaceutical Giant